METHOTREXATE VERSUS APREMILAST IN THE TREATMENT OF PLAQUE PSORIASIS
Phase 4
- Conditions
- Health Condition 1: L400- Psoriasis vulgaris
- Registration Number
- CTRI/2023/03/051052
- Lead Sponsor
- Trish Larissa Miranda
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1)Male and female patients above 18 years with plaque psoriasis.
2)Involvement of 20% or more of body surface area with plaque psoriasis.
Exclusion Criteria
1)Pregnancy
2)Lactating women.
3)Immunosuppressed individuals
4)Patients with pustular psoriasis.
5)Patients with erythrodermic psoriasis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Outcome name-Psoriasis Area Severity Index(PASI) based on the following parameters:- <br/ ><br>1. Erythema <br/ ><br>2. Induration <br/ ><br>3. Desquamation or scaling <br/ ><br>Timepoint: Week 0-Baseline <br/ ><br>Week 4 <br/ ><br>Week 8 <br/ ><br>Week 12 <br/ ><br>Week 16
- Secondary Outcome Measures
Name Time Method PASI-75-To compare the efficacy of Methotrexate and Apremilast by comparing their PASI-75 scores that is time taken for 75% or more reduction of psoriasis lesions from baseline lesions.Timepoint: Not fixed,depending on the time taken to show 75% or more improvement from baseline lesions for each of the 2 drugs separately.